The event was an Earnings Conference Call with Analysts, Institutional Investors, Funds, and other investors.
The call was held on Monday, July 27, 2026 to discuss the company's Unaudited Financial Results for the quarter ended June 30, 2026 (Q2 FY26).
The stated purpose was to discuss the company's Financial Results for the period.
The meeting was held on the same day as the results announcement (July 27, 2026).
Management participants were not explicitly listed in the disclosure.
The audio recording of the earnings conference call is available on the company's website and can be accessed at the weblink: https://senorespharma.com/investor-meet/.
The company explicitly stated that no Unpublished Price Sensitive Information (UPSI) was shared or discussed during the call.
Additional Notes Section
The disclosure is a formal compliance letter addressed to the Listing Departments of BSE Limited and the National Stock Exchange of India Limited.
The letter is signed by Deval Rajnikant Shah, Whole Time Director & CFO (DIN: 00332722).
No financial data, guidance, or strategic updates were disclosed in this announcement.
The document serves purely as an intimation of the event's occurrence and the availability of its recording.
